Silvia Bio Raises £3M for Biomanufacturing

University of Sheffield spinout Silvia Bio has raised £3 million to improve the mammalian cells used to manufacture biologic medicines.

What happened

The seed round was led by Northern Gritstone with participation from the Parkwalk Northern Universities Venture Fund, UK Innovation & Science Seed Fund, Wren Capital and angel investors. Silvia Bio analyses cells used to produce biologic medicines such as antibodies and gene therapies. Its platform is designed to identify biological bottlenecks that reduce cell performance and help biopharma companies improve manufacturing yields. The company says it has worked with several large pharmaceutical companies but has not publicly named them.

Why it matters

Advanced medicines can be difficult and expensive to manufacture because living cells behave unpredictably and may produce inconsistent yields. Improving cell performance can lower production costs and increase output without changing the therapeutic molecule itself.

The bigger picture

Biomanufacturing is an increasingly important infrastructure layer behind new therapies. Silvia Bio's value will depend on whether its insights translate into reproducible improvements at industrial scale and whether customers integrate the platform into long development and manufacturing cycles.